

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 20, 2025

Brilliant Violet 421(TM) anti-human TIGIT (VSTM3)

RRID:AB_2632925

Type: Antibody

Proper Citation

(BioLegend Cat# 372710, RRID:AB_2632925)

Antibody Information

URL: http://antibodyregistry.org/AB_2632925

Proper Citation: (BioLegend Cat# 372710, RRID:AB_2632925)

Target Antigen: TIGIT

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 421(TM) anti-human TIGIT (VSTM3)

Description: This monoclonal targets TIGIT

Target Organism: human

Clone ID: Clone A15153G

Antibody ID: AB_2632925

Vendor: BioLegend

Catalog Number: 372710

Alternative Catalog Numbers: 372709

Record Creation Time: 20231110T034722+0000

Record Last Update: 20240725T025913+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human TIGIT (VSTM3).

No alerts have been found for Brilliant Violet 421(TM) anti-human TIGIT (VSTM3).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Xu X, et al. (2024) Phase separation of chimeric antigen receptor promotes immunological synapse maturation and persistent cytotoxicity. *Immunity*, 57(12), 2755.

Wang R, et al. (2024) H3K9 lactylation in malignant cells facilitates CD8+ T cell dysfunction and poor immunotherapy response. *Cell reports*, 43(9), 114686.

Kuo HH, et al. (2018) Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T Cells. *Immunity*, 48(6), 1183.